KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Cash: 2011-2025

Historic Change in Cash for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $8.1 million.

  • Supernus Pharmaceuticals' Change in Cash rose 139.72% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.1 million, marking a year-over-year increase of 291.35%. This contributed to the annual value of -$5.7 million for FY2024, which is 68.32% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Change in Cash stood at $8.1 million, which was down 71.90% from $28.9 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Change in Cash registered a high of $369.1 million during Q1 2023, and its lowest value of -$437.5 million during Q2 2023.
  • In the last 3 years, Supernus Pharmaceuticals' Change in Cash had a median value of $8.1 million in 2025 and averaged $5.4 million.
  • Examining YoY changes over the last 5 years, Supernus Pharmaceuticals' Change in Cash showed a top increase of 520.75% in 2023 and a maximum decrease of 858.05% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Cash (Quarterly) stood at -$11.8 million in 2021, then crashed by 55.08% to -$18.4 million in 2022, then dropped by 8.49% to -$19.9 million in 2023, then soared by 288.94% to $37.7 million in 2024, then soared by 139.72% to $8.1 million in 2025.
  • Its Change in Cash stands at $8.1 million for Q3 2025, versus $28.9 million for Q2 2025 and $46.5 million for Q1 2025.